In a report released yesterday, Yasmeen Rahimi from Roth Capital reiterated a Buy rating on Enanta Pharmaceuticals (NASDAQ: ENTA), with a price target of $130. The company’s shares closed yesterday at $93.84.
According to TipRanks.com, Rahimi is a 5-star analyst with an average return of 55.6% and a 57.1% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Soleno Therapeutics Inc, and Evofem Biosciences Inc.
Currently, the analyst consensus on Enanta Pharmaceuticals is a Moderate Buy with an average price target of $113.33, representing a 20.8% upside. In a report issued on July 27, JMP Securities also reiterated a Buy rating on the stock with a $120 price target.
.
See today’s analyst top recommended stocks >>
Based on Enanta Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $12.56 million. In comparison, last year the company had a GAAP net loss of $8.43 million.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENTA in relation to earlier this year. Last month, Jay Luly, the President & CEO of ENTA bought 8,498 shares for a total of $99,936.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It offers the two protease inhibitors Maviret and the Viekira Pak for the treatment of chronic hepatitis C virus.
